CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region. Under the agreement, Biopharma and Cigalah Healthcare will support the commercialization and distribution. ...

ImmunityBio Inc (NASDAQ:IBRX) stock is maintaining a confirmed Golden Cross, with the stock now trading roughly 170% above its 200-day moving average — a measurable signal of sustained long-term trend strength.IBRX stock is currently trading near $8.04, while the 200-day moving average sits at approximately $2.95. The Golden Cross was established after the 50-day moving average rose above the 200-day moving average, and the widening gap between the two continues to reflect a strong upward trend.IBRX Price H ...

Key Takeaways IBRX soars 41.9% after the EC cleared Anktiva plus BCG for BCG-unresponsive NMIBC CIS in the EU.The IBRX combo therapy showed a 71% complete response rate in the phase II/III QUILT-3.032 study.IBRX to submit more data to confirm Anktiva's efficacy and safety, with EU approval subject to annual renewal.Shares of ImmunityBio, Inc. (IBRX) soared 41.9% on Wednesday after the company announced that the European Commission (EC) has granted conditional marketing authorization for Anktiva (nogapendeki ...

Core Insights - ImmunityBio (IBRX) shares surged 41.9% to close at $8.54, reversing a previous 7.1% loss over the past four weeks, supported by high trading volume [1][2] Company Developments - The significant share price increase was driven by the European Commission granting conditional approval for ImmunityBio's Anktiva plus BCG therapy for treating BCG-unresponsive non-muscle invasive bladder cancer, expanding its market presence to 33 countries [2] - This approval marks the first immunotherapy authorized in Europe for this specific indication, enhancing the company's growth prospects [2] Financial Expectations - ImmunityBio is projected to report a quarterly loss of $0.08 per share, reflecting a year-over-year increase of 46.7%, with expected revenues of $37.1 million, up 391.4% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 6.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - ImmunityBio operates within the Zacks Medical - Biomedical and Genetics industry, where Mirum Pharmaceuticals, another company in the sector, has seen a 2.2% increase in its stock price, closing at $105.1, with an 11.9% return over the past month [4] - Mirum Pharmaceuticals has a consensus EPS estimate that has changed by +50.9% over the past month, indicating a significant year-over-year change of +104.1% [5]

We recently published 10 Market Winners With Stunning Gains. Immunitybio Inc. (NASDAQ:IBRX) was one of the best performers on Wednesday. ImmunityBio soared to a new 52-week high on Wednesday, as investors gobbled up shares over an aggressive international expansion for its therapy, Anktiva. At intra-day trading, the stock climbed to its highest price of $8.68 before trimming gains to end the day just up by 41.86 percent at $8.54 apiece. In a statement, Immunitybio Inc. (NASDAQ:IBRX) said that the Europ ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it has initiated a Phase 2 clinical trial evaluating a novel combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). Meanwhile, on January 26, ImmunityBio Inc. (NASDAQ:IBRX) amended a $505 million convertible promissory note with Nant Capital LLC, allowing the noteholder to convert any portion of the outstanding p ...

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted conditional marketing authorization for Anktiva to treat bladder cancer. Trading volume reached 78.5 million shares, about 178% above its three-month average of 28.2 million shares. ImmunityBio IPO'd in 2015 and has fallen 75% since going public. How the markets moved today The S&P 500 rose 0.53% to finish ...

Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another huge market. Approved... again ImmunityBio's oncology drug Anktiva had already been approved as a treatment for certain forms of bladder cancer as early as 2024, for the record, when the United States' FDA gave the immunotherapy the green light. The Unite ...

Bladder Cancer Treatment Receives ApprovalThe authorization by the European Commission allows ImmunityBio to establish a substantial commercial footprint across four regulatory jurisdictions in less than two years from its initial FDA approval. This rapid expansion is pivotal as it includes key markets like the Kingdom of Saudi Arabia, where ANKTIVA has received authorization for two indications, highlighting its growing acceptance and potential impact on ImmunityBio’s market reach.As part of the conditiona ...

ImmunityBio, Inc. ( IBRX ) stock has been on a very bullish run. The investor confidence comes from the potential of a chemo‑free immunotherapy platform, which is led by Anktiva. The short idea here is that Anktiva is an IL‑15 superagonist that fuelsI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foun ...